Phase I-II study of high dose epirubicin plus cisplatin in unresectable non-small-cell lung cancer: searching for the maximal tolerated dose.

The purpose of this study was to search for the maximal tolerated dose of cisplatin in the cisplatin plus high-dose epirubicin combination for patients with non-small-cell lung cancer. The following range of cisplatin dosages were tested in a phase I study: 75, 90, 105, and 120 mg/m2 in combination with epirubicin 120 mg/m2 every 3 weeks. Eligibility consisted of previously untreated stage IIIb or IV non-small-cell lung cancers, Eastern Cooperative Oncology Group Performance Status less than or equal to 2, age less than or equal to 70 years, measurable disease, adequate blood counts, chemistry, cardiac function, and no brain metastasis. The maximal tolerated dose was defined as the dose level of cisplatin for which two of three patients or three of six patients developed one or more limiting toxicities during the first course of therapy. Afterward, the maximal tolerated dose of cisplatin was adopted in a subsequent phase II study. Three centers enrolled 42 patients: 18 in phase I and 24 in phase II. The maximal tolerated dose was almost reached at the last dose level (i.e., 120 mg/m2). Taking into account the total duration of the treatment, the real dose intensity for patients treated at the fourth dose level (120 mg/m2) did not differ from that of the third dose level (105 mg/m2). The latter dosage was therefore considered as the maximal tolerated one. In the subsequent phase II study, the median number of cycles received per patient was three (range: one to eight). Fifty percent required a dose reduction of either epirubicin, cisplatin, or both. The main toxicity was neutropenia, resulting in 10 episodes of febrile grade IV neutropenia requiring readmission. Other toxicities were mild to moderate. There was no toxic-related death. On intent-to-treat analysis, 10 patients (33%) achieved an objective response. Among them were three complete responders. Median survival was 8 months. We observed neither detraction nor improvement of quality of life as assessed using the European Organization for Research and Treatment of Cancer QLQ-C30-LC13. Given every 3 weeks in combination with epirubicin 120 mg/m2, the maximal tolerated cisplatin dose is 105 mg/m2. This combination yields activity in non-small-cell lung cancer.

[1]  F. Pannuti,et al.  Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer. , 1998, Lung cancer.

[2]  B. Housset,et al.  Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[4]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[5]  F. Pannuti,et al.  A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small-cell lung cancer (NSCLC). , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  E. Smit,et al.  A phase II study of high dose epirubicin in unresectable non small cell lung cancer. , 1992, British Journal of Cancer.

[7]  R. Wierzbicki,et al.  Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Pannuti,et al.  Activity of high-dose epirubicin in advanced non-small cell lung cancer. , 1991, European journal of cancer.

[9]  S. Kaye,et al.  Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Hryniuk,et al.  The calculation of received dose intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. K. Yeung,et al.  A functional assessment of the relative cardiotoxicity of adriamycin and epirubicin in the rat. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  H. Hansen,et al.  Phase II trial of epirubicin in advanced squamous, adeno- and large cell carcinoma of the lung. , 1984, European journal of cancer & clinical oncology.

[13]  E. Gehan,et al.  The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.

[14]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[15]  M. Ranson,et al.  Chemotherapy in non-small cell lung cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Jassem,et al.  Randomized phase II trial of high-dose 4'-epi-doxorubicin + cyclophosphamide versus high-dose 4'-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer. , 1992, Oncology.

[17]  A. Gregor Controversies in the treatment of non-small cell lung cancer. , 1991, European journal of cancer.

[18]  A. Riva,et al.  Phase II study of high-dose epirubicin in non-small cell lung cancer. , 1990, European journal of cancer.

[19]  F. Pannuti,et al.  High-dose epirubicin for untreated patients with advanced tumours: a phase I study. , 1990, European journal of cancer.